BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: De Clercq E. The race for interferon-free HCV therapies: a snapshot by the spring of 2012: Interferon-free HCV therapies. Rev Med Virol 2012;22:392-411. [DOI: 10.1002/rmv.1727] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.6] [Reference Citation Analysis]
Number Citing Articles
1 De Clercq E. Antivirals: Past, present and future. Biochemical Pharmacology 2013;85:727-44. [DOI: 10.1016/j.bcp.2012.12.011] [Cited by in Crossref: 74] [Cited by in F6Publishing: 65] [Article Influence: 8.2] [Reference Citation Analysis]
2 De Clercq E. Current race in the development of DAAs (direct-acting antivirals) against HCV. Biochemical Pharmacology 2014;89:441-52. [DOI: 10.1016/j.bcp.2014.04.005] [Cited by in Crossref: 69] [Cited by in F6Publishing: 67] [Article Influence: 8.6] [Reference Citation Analysis]
3 Chen YL, Yokokawa F, Shi PY. The search for nucleoside/nucleotide analog inhibitors of dengue virus. Antiviral Res 2015;122:12-9. [PMID: 26241002 DOI: 10.1016/j.antiviral.2015.07.010] [Cited by in Crossref: 46] [Cited by in F6Publishing: 42] [Article Influence: 6.6] [Reference Citation Analysis]
4 Li G, De Clercq E. Current therapy for chronic hepatitis C: The role of direct-acting antivirals. Antiviral Res. 2017;142:83-122. [PMID: 28238877 DOI: 10.1016/j.antiviral.2017.02.014] [Cited by in Crossref: 93] [Cited by in F6Publishing: 83] [Article Influence: 18.6] [Reference Citation Analysis]
5 Wilfret DA, Walker J, Adkison KK, Jones LA, Lou Y, Gan J, Castellino S, Moseley CL, Horton J, de Serres M. Safety, tolerability, pharmacokinetics, and antiviral activity of GSK2336805, an inhibitor of hepatitis C virus (HCV) NS5A, in healthy subjects and subjects chronically infected with HCV genotype 1. Antimicrob Agents Chemother. 2013;57:5037-5044. [PMID: 23896477 DOI: 10.1128/aac.00910-13] [Cited by in Crossref: 17] [Cited by in F6Publishing: 8] [Article Influence: 1.9] [Reference Citation Analysis]
6 Ahmad T, Yin P, Saffitz J, Pockros PJ, Lalezari J, Shiffman M, Freilich B, Zamparo J, Brown K, Dimitrova D, Kumar M, Manion D, Heath-Chiozzi M, Wolf R, Hughes E, Muir AJ, Hernandez AF. Cardiac dysfunction associated with a nucleotide polymerase inhibitor for treatment of hepatitis C. Hepatology 2015;62:409-16. [PMID: 25251156 DOI: 10.1002/hep.27488] [Cited by in Crossref: 38] [Cited by in F6Publishing: 36] [Article Influence: 5.4] [Reference Citation Analysis]
7 Qi H, Olson CA, Wu NC, Ke R, Loverdo C, Chu V, Truong S, Remenyi R, Chen Z, Du Y, Su SY, Al-Mawsawi LQ, Wu TT, Chen SH, Lin CY, Zhong W, Lloyd-Smith JO, Sun R. A quantitative high-resolution genetic profile rapidly identifies sequence determinants of hepatitis C viral fitness and drug sensitivity. PLoS Pathog 2014;10:e1004064. [PMID: 24722365 DOI: 10.1371/journal.ppat.1004064] [Cited by in Crossref: 51] [Cited by in F6Publishing: 44] [Article Influence: 6.4] [Reference Citation Analysis]
8 Xue W, Jiao P, Liu H, Yao X. Molecular modeling and residue interaction network studies on the mechanism of binding and resistance of the HCV NS5B polymerase mutants to VX-222 and ANA598. Antiviral Res 2014;104:40-51. [PMID: 24462692 DOI: 10.1016/j.antiviral.2014.01.006] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 3.9] [Reference Citation Analysis]
9 Han D, Wang H, Wujieti B, Zhang B, Cui W, Chen BZ. Insight into the drug resistance mechanisms of GS-9669 caused by mutations of HCV NS5B polymerase via molecular simulation. Comput Struct Biotechnol J 2021;19:2761-74. [PMID: 34093991 DOI: 10.1016/j.csbj.2021.04.026] [Reference Citation Analysis]
10 De Clercq E. Human viral diseases: what is next for antiviral drug discovery? Curr Opin Virol 2012;2:572-9. [PMID: 22846888 DOI: 10.1016/j.coviro.2012.07.004] [Cited by in Crossref: 25] [Cited by in F6Publishing: 18] [Article Influence: 2.5] [Reference Citation Analysis]
11 De Clercq E, Li G. Approved Antiviral Drugs over the Past 50 Years. Clin Microbiol Rev. 2016;29:695-747. [PMID: 27281742 DOI: 10.1128/cmr.00102-15] [Cited by in Crossref: 592] [Cited by in F6Publishing: 276] [Article Influence: 98.7] [Reference Citation Analysis]
12 Everson GT, Sims KD, Rodriguez-Torres M, Hézode C, Lawitz E, Bourlière M, Loustaud-Ratti V, Rustgi V, Schwartz H, Tatum H. Efficacy of an interferon- and ribavirin-free regimen of daclatasvir, asunaprevir, and BMS-791325 in treatment-naive patients with HCV genotype 1 infection. Gastroenterology. 2014;146:420-429. [PMID: 24184132 DOI: 10.1053/j.gastro.2013.10.057] [Cited by in Crossref: 158] [Cited by in F6Publishing: 151] [Article Influence: 17.6] [Reference Citation Analysis]
13 Wang X, Fan X, Deng H, Zhang X, Zhang K, Li N, Han Q, Lv Y, Liu Z. Efficacy and safety of glecaprevir/pibrentasvir for chronic hepatitis C virus genotypes 1-6 infection: A systematic review and meta-analysis. Int J Antimicrob Agents 2019;54:780-9. [PMID: 31284039 DOI: 10.1016/j.ijantimicag.2019.07.005] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
14 De Clercq E. A Cutting-Edge View on the Current State of Antiviral Drug Development. Med Res Rev. 2013;Epub ahead of print. [PMID: 23495004 DOI: 10.1002/med.21281] [Cited by in Crossref: 39] [Cited by in F6Publishing: 35] [Article Influence: 4.3] [Reference Citation Analysis]
15 Shalom-Elazari H, Zazrin-Greenspon H, Shaked H, Chill JH. Global fold and backbone dynamics of the hepatitis C virus E2 glycoprotein transmembrane domain determined by NMR. Biochim Biophys Acta 2014;1838:2919-28. [PMID: 25109935 DOI: 10.1016/j.bbamem.2014.07.023] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
16 Biomy R, Abdelshafy M, Abdelmonem A, Abu-Elenin H, Ghaly G. Effect of Chronic Hepatitis C Virus Treatment by Combination Therapy on Cardiovascular System. Clin Med Insights Cardiol 2017;11:1179546817713204. [PMID: 28804248 DOI: 10.1177/1179546817713204] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]